BioXcel Therapeutics (BTAI) Other Non Operating Income (2022 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Other Non Operating Income of $1.5 million for Q1 2026, down 76.84% year-over-year from $6.6 million in Q1 2025, and down 16.17% quarter-over-quarter from $1.8 million in Q4 2025.
BioXcel Therapeutics (BTAI) Other Non Operating Income (2022 - 2026) Analysis & Trends
BioXcel Therapeutics' Other Non Operating Income history runs 5 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- In Q1 2026, Other Non Operating Income fell 76.84% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at -$8.6 million (down 132.05% YoY), while the FY2025 annual figure was -$3.5 million, down 117.44% from the prior year.
- Other Non Operating Income for Q1 2026 stood at $1.5 million, down from $1.8 million in the prior quarter.
- The five-year high for Other Non Operating Income was $12.0 million in Q2 2024, with the low at -$12.5 million in Q3 2025.
- The 5-year median for Other Non Operating Income is $537000.0 (2023), against an average of $1.2 million.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income jumped 96440.0% in 2024, then plunged 360.45% in 2025.
- BioXcel Therapeutics' Other Non Operating Income stood at -$480000.0 in 2022, then surged by 122.5% to $108000.0 in 2023, then soared by 2953.7% to $3.3 million in 2024, then slumped by 45.06% to $1.8 million in 2025, then fell by 16.17% to $1.5 million in 2026.
- Business Quant data shows BTAI's Other Non Operating Income at $1.5 million in Q1 2026, $1.8 million in Q4 2025, and -$12.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | BioXcel Therapeutics | 24.93 Mn | 24.93 Mn | 160,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -394,000.00 |
| Mar 31, 2026 | 1.52 Mn |
| Dec 31, 2025 | 1.81 Mn |
| Sep 30, 2025 | -12.55 Mn |
| Jun 30, 2025 | 657,000.00 |
| Mar 31, 2025 | 6.56 Mn |
| Dec 31, 2024 | 3.30 Mn |
| Sep 30, 2024 | 4.82 Mn |
| Jun 30, 2024 | 12.03 Mn |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | 108,000.00 |
| Sep 30, 2023 | -5,000.00 |
| Jun 30, 2023 | 537,000.00 |
| Mar 31, 2023 | -246,000.00 |
| Dec 31, 2022 | -480,000.00 |
| Sep 30, 2022 | 62,000.00 |